Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.
High evidence 0Moderate evidence 0Low evidence 4Very low evidence 2
CT-388/enicepatide is shown as an investigational or pipeline evidence record. Findings describe what studies and reports observed; they do not endorse use or establish personal suitability.
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
CT-388/enicepatideINVESTIGATIONAL
Weight changeDecrease
Low evidence
Phase 1 (4 once-weekly doses) produced dose-dependent weight loss by day 29 in overweight/obese participants.
SourceChakravarthy MV et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP r...Source
Scope limitsanimal data; human relevance uncertain; conference/abstract-level; identifier not fully verified
Comparatorsplacebo
CT-388/enicepatideINVESTIGATIONAL
Weight changeDecrease
Very low evidence
CT-388 (Roche/Genentech, ex-Carmot) is a once-weekly subcutaneous GLP-1/GIP dual agonist. In a phase 2 obesity trial it achieved a statistically significant...
Full findingCT-388 (Roche/Genentech, ex-Carmot) is a once-weekly subcutaneous GLP-1/GIP dual agonist. In a phase 2 obesity trial it achieved a statistically significant placebo-adjusted weight loss of 22.5% at 48 weeks at the highest dose (24 mg), without reaching a plateau; 87% of the 24 mg group achieved >=10% and 47.8% >=20% weight loss, and 54% reached BMI <30 (vs 13% placebo).
PopulationPhase 2: 469 adults with obesity or overweight + >=1 comorbidity, dose-escalation up to 24 mg once-weekly s.c., 48 weeks, randomised double-blind placebo-controlled
Fundingindustry - Roche (trial sponsor; inferred from registration trial)
Scope limitsno outcome data yet (ongoing)
Comparatorsplacebo
CT-388/enicepatideINVESTIGATIONAL
Weight changeDecrease
Very low evidence
Phase 2 topline: clinically meaningful, statistically significant placebo-adjusted weight loss at the highest dose at 48 weeks.
SourceRoche/Genentech press release: Roche announces positive Phase II results for dual GLP-1/G...Source
Fundingindustry - Roche (trial sponsor; inferred from registration trial)
Scope limitsidentifier not fully verified; no outcome data yet (ongoing)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
CT-388/enicepatideINVESTIGATIONAL
Glycaemic controlDecrease
Low evidence
Improved glycaemic parameters during fasting and oral glucose tolerance testing in phase 1; HbA1c reductions reported in a phase 1b T2D cohort (conference).
SourceChakravarthy MV et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP r...Source
PopulationPhase 1 overweight/obese (NCT04838405); ADA abstract 763-P = 12-wk cohort adults with obesity + T2D
Fundingindustry - Roche
Scope limitsanimal data; human relevance uncertain; conference/abstract-level; identifier not fully verified
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
CT-388/enicepatideINVESTIGATIONAL
Pharmacology and mechanismNot directional
Low evidence
Unimolecular peptide dual GLP-1R/GIPR agonist that is cAMP signal-biased at both receptors (minimal receptor internalisation vs native ligands); PK supports...
SourceChakravarthy MV et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP r...Source
Full findingUnimolecular peptide dual GLP-1R/GIPR agonist that is cAMP signal-biased at both receptors (minimal receptor internalisation vs native ligands); PK supports once-weekly dosing.
The Echo Compendium